
Help your patients feel prepared
The US Hereditary Angioedema Association (HAEA) 2020 Guidelines state that patients with hereditary angioedema (HAE) are advised to have immediate access to at least two doses of on-demand medication to treat acute attacks.1 This means that if you decide to prescribe long-term prophylaxis (LTP), your patients may still need on-demand treatment.1
SAJAZIR™ (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.2
Insights from the US HAEA Medical Advisory Board 2020 Guidelines
The diagnosis and treatment of HAE is outlined in the US HAEA Medical Advisory Board 2020 Guidelines.1 The evidence-backed recommendations – based on a literature reviewed by several expert clinicians with firsthand experience in treating HAE – were approved by a unanimous vote and are an expansion of the 2013 guidelines.1
Developing an effective treatment plan for your patients
The guidelines state that every individual with HAE should have a personalized treatment plan consisting of on-demand treatment and consideration of the need for short- and long-term prophylaxis.1
| Form of treatment | Recommendation |
|---|---|
| On-demand treatment | It is advised that your patients have ready access to at least two standard doses of FDA-approved on-demand medication for the treatment of acute attacks without exception. |
| Prophylactic treatment | Short-term prophylaxis is indicated when patients are at risk of developing an attack due to known triggers (medical procedures or stressful life events, etc.). The decision on when to use long-term prophylaxis should reflect your patients’ individual needs. |
Table 1: The recommendations for the treatment of HAE.1
Help your patients feel prepared with SAJAZIR™ (icatibant) injection
Although LTP has the potential to normalize the lives of patients with HAE, immediate access to on-demand treatment like SAJAZIR is still required to ensure patients are always prepared.1 You can make sure your patients are prepared for an acute attack by having at least two doses of on-demand treatment, like SAJAZIR, on hand.1
4 reasons to choose SAJAZIR
1
Convenient
SAJAZIR is portable, may be stored at room temperature, and can be self-administered* as soon as signs of an acute attack appear.2
*SAJAZIR injection is a prefilled syringe for subcutaneous use.2 Patients should not inject SAJAZIR until they have been trained by their healthcare provider or a Cycle Vita Clinical Education Manager.
2
Effective
SAJAZIR reduces symptoms by 50% in a median time of 2 hours and achieves almost complete symptom relief in a median time of 8 hours.2
The most common adverse reactions with SAJAZIR were injection site reactions. Other common adverse reactions include pyrexia, transaminase increase, dizziness and rash.
3
Access
With Cycle Vita™, our comprehensive patient support program, treatment may begin immediately through the Bridge Program.** Your patients may also benefit from the Co-Pay Assistance Program – 96% of patients paid a $0 co-pay in 2025.3
4
Support
Your patients may receive continuous product and clinical support** with a dedicated Clinical Education Manager. This includes 1-to-1 self-administration* training at home, in clinic, or online.
*SAJAZIR injection is a prefilled syringe for subcutaneous use. Patients should not inject SAJAZIR until they have been trained by their healthcare provider or a Cycle Vita Clinical Education Manager.
STUDY DESIGN2
SAJAZIR’s safety and efficacy in acute HAE attacks was evaluated in 3 controlled trials. Trial 1 (n=98) was a randomized, placebo-controlled, double-blind, parallel-group study on moderate to severe cutaneous or abdominal or mild to moderate attacks of HAE. Patients were treated with either 30 mg of icatibant or placebo. Median time to 50% reduction in a 3-item visual analog score of skin swelling, skin pain, and abdominal pain, was 2 hours (n=43, 95% CI 1.5, 3.0) vs. 19.8 hours (n=45, 95% CI 6.1, 26.3) in placebo.
**Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.
References
1. Busse PJ, et al. 2021. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J of Aller and Clin Immunol: In Practice; 9:132-150.e3. https://doi.org/10.1016/j.jaip.2020.08.046.
2. SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.
3. Data on File: Ref-00101.
